DURECT Corporation Accounts Receivables 2011-2026 | DRRX

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables DURECT Corporation

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.26 M	3.42 M	6.48 M	494 K	2.31 M	1.76 M	2.38 M	1.15 M	2.22 M	2.12 M	2.35 M	2.17 M	3.45 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
6.48 M	494 K	2.43 M

Quarterly Accounts Receivables DURECT Corporation

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
511 K	330 K	1.02 M	1.01 M	1.02 M	883 K	1.3 M	1.4 M	3.42 M	3.23 M	-	960 K	6.48 M	946 K	816 K	993 K	940 K	940 K	940 K	940 K	494 K	2.31 M	2.31 M	2.31 M	1.76 M	1.76 M	1.76 M	1.76 M	2.38 M	2.38 M	2.38 M	2.38 M	1.15 M	1.15 M	1.15 M	1.15 M	2.22 M	2.22 M	2.22 M	2.22 M	2.12 M	2.12 M	2.12 M	2.12 M	2.35 M	2.35 M	2.35 M	2.35 M	2.17 M	2.17 M	2.17 M	2.17 M	3.45 M	3.45 M	3.45 M	3.45 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
6.48 M	330 K	1.93 M

Accounts Receivables of other stocks in the Drug manufacturers industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
Alimera Sciences ALIM	34.5 M	-	-	$ 142 M	USA
Adamis Pharmaceuticals Corporation ADMP	1.05 M	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	68.8 M	-	-	$ 754 M	USA
Canopy Growth Corporation CGC	47.5 M	$ 1.2	0.42 %	$ 129 M	Canada
AcelRx Pharmaceuticals ACRX	160 K	-	7.5 %	$ 6.35 M	USA
Agile Therapeutics AGRX	3.39 M	-	10.11 %	$ 58.2 M	USA
Catalent CTLT	921 M	-	-	$ 11.5 B	USA
Eagle Pharmaceuticals EGRX	72.4 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	387 M	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	673 K	-	-	$ 36.6 M	USA
Emergent BioSolutions EBS	191 M	$ 12.84	2.8 %	$ 657 M	USA
Athenex ATNX	27.9 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	34.1 M	$ 21.5	-0.12 %	$ 2.05 B	France
Evolus EOLS	47.7 M	$ 6.03	-10.27 %	$ 374 M	USA
Harrow Health HROW	15.1 M	$ 54.06	8.3 %	$ 1.76 B	USA
Jupiter Wellness JUPW	512 K	-	-	$ 33.6 M	USA
China Pharma Holdings CPHI	232 K	$ 1.23	1.65 %	$ 21.5 M	China
Bausch Health Companies BHC	2 B	$ 7.51	4.16 %	$ 2.74 B	Canada
Lannett Company LCI	56.2 M	-	1.15 %	$ 7.11 M	USA
Neoleukin Therapeutics NLTX	65.4 K	-	-	$ 193 M	Canada
Cumberland Pharmaceuticals CPIX	11.7 M	$ 3.95	-0.77 %	$ 55.5 M	USA
Organogenesis Holdings ORGO	110 M	$ 4.36	-5.93 %	$ 574 M	USA
Pacira BioSciences PCRX	113 M	$ 25.21	3.07 %	$ 1.17 B	USA
Sonoma Pharmaceuticals SNOA	2.23 M	$ 3.73	2.46 %	$ 4.63 M	USA
Rockwell Medical RMTI	10.9 M	$ 0.98	13.92 %	$ 22.9 M	USA
PetIQ PETQ	143 M	-	1.64 %	$ 400 M	USA
Perrigo Company plc PRGO	642 M	$ 14.36	3.42 %	$ 1.97 B	USA
ProPhase Labs PRPH	37.1 M	-	-	$ 5.07 M	USA
Veru VERU	3.96 M	$ 2.28	0.58 %	$ 308 M	USA
Radius Health RDUS	20.3 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	16.6 M	-	-4.76 %	$ 65.3 M	USA
cbdMD YCBD	622 K	$ 1.11	-4.31 %	$ 4.79 M	USA
Relmada Therapeutics RLMD	512 K	$ 4.11	-6.06 %	$ 124 M	USA
OptiNose OPTN	19.9 M	-	-	$ 1.08 B	USA
Assertio Holdings ASRT	47.7 M	$ 9.62	5.25 %	$ 683 M	USA
PLx Pharma PLXP	634 K	-	-27.8 %	$ 2.56 M	USA
SCYNEXIS SCYX	2.1 M	$ 0.64	-0.03 %	$ 30.6 M	USA
Tilray TLRY	86.2 M	$ 9.43	-3.03 %	$ 5.83 B	Canada
TherapeuticsMD TXMD	32.4 M	$ 1.79	8.78 %	$ 18.7 M	USA
Zomedica Corp. ZOM	1.2 M	-	-0.21 %	$ 98 M	USA